GID BIO forms with a mission to treat degenerative musculoskeletal and systemic diseases through innovative, safe and effective cellular medicine therapies that make cellular medicine possible for everyone.

2010

2012

GID develops proprietary disposable single-use devices with scientific methods, controls, and reagents to extract and process a patient's own adipose tissue for isolation and concentration of progenitor cellular implants in real-time at the point-of-care.

GID partners with LifeCell to develop and release Revolve product for advanced fat grafting technology.

GID completes two IRB-approved studies:

"Use of Autologous Adipose-Derived Stromal Vascular Fraction to Treat Osteoarthritis of the Knee: A Feasibility and Safety Study" with 10 knees in six patients led by Jaime R. Garza, Daniel Santa Maria, Timothy Palomera, Gregory A Dumanian and Severiano Dos-Anjos.; and

2013

"Adipose Derived Stromal Cell (ADSC) Injections for Pain Management of Osteoarthritis in the Human Knee Joint" with eight knees in six patients led by Peter B. Fodor, MD, FACS and Stephen G. Paulseth, PT, MS, DPT, SCS, ATC.

2014

GID reduces an entire Good Manufacturing Practices (GMP) cell-processing facility into a single disposable device so that scalable cell processing can become available to hospitals, medical practices, and other surgical and clinical settings for a broad range of therapeutic applications including orthopedic, musculoskeletal, dermal and organ therapies.

SVF-2 Device

GID's SVF-2 device uniquely isolates, concentrates and extracts Stromal Vascular Fraction (SVF) cells with elimination of inflammatory blood cells and adipocytes.

2015

GID begins engagement with the FDA for its first FDA-approved study: randomized, double-blinded, placebo-controlled trial evaluating SVF injections for osteoarthritis of the knee.

Results of the two IRB-approved studies are published in the *Journal of Regenerative Medicine* (March 2015) and *Aesthetic Surgery Journal* (August 2015) including no adverse events at three-months and one-year-post-procedure, and decreased knee pain for all patients after three months.

FDA approves the clinical trial design: "Clinical Efficacy of Intra-articular Stromal Vascular Fraction for the Treatment of Knee Osteoarthritis: A prospective, randomized, controlled clinical trial" for 39 patients.

2016

GID completes FDA clinical trial with one-year results and meets all efficacy endpoints.

- Results show that SVF treatment is statistically significant and is superior to placebo.
- One-year trial results demonstrate a 70% responder rate with a median 85% improvement in pain and function using the WOMAC OA scale.
- No serious adverse events are reported.

2018

Dr. Ricardo J. Rodriguez, a plastic surgeon in Baltimore and past president of IFATS claims: "Cells are significantly more important than any other anti-inflammatory drug on the market."

GID is the first cellular medicine company to meet clinical trial endpoints and establish initial efficacy for its randomized clinical trial investigating the use of SVF for treatment of osteoarthritis of the knee.

The FDA announces that "Stem cell therapies hold significant potential to improve human health."

2019



The American Medical Association (AMA) grants two Class III CPT codes: 0565T and 0566T for reimbursement. CPT code 0565T is used for harvesting and creating the cellular implant. CPT code O566T is used for the injection of the implant under ultrasound guidance.

Bruce Bunnell, Ph.D., professor, director of the Tulane Center for Stem Cell Research & Regenerative Medicine, says, "There is potential for GID's device and therapy to be a tremendous benefit to patients. The right types of healing cells are extracted and control inflammation in patients with osteoarthritis. These cells work better than any other cells or drug currently available. Once FDA-approved and widely available, most patients will likely want to use their own healing cells rather than other drugs or surgical options."

Final pivotal clinical trial to support pending FDA approval of GID's SVF-2 device and cellular therapy is submitted to the FDA for treatment of osteoarthritis of the knee.

One-year clinical trial results are accepted for publication in the *American Journal of Sports Medicine*.

Approval by FDA of final pivotal study. 180 subjects in combined efficacy and safety studies.

- Recruitment begins for final pivotal FDA studies for OA.

Publication of trial results for: "Clinical Efficacy of Intra-articular Stromal Vascular Fraction for the Treatment of Knee Osteoarthritis: A prospective, randomized, controlled clinical trial."

AMA AMERICAN MEDICAL ASSOCIATION

2020

The CPT codes are being used to help establish an initial reimbursement strategy for Medicare for the use of the GID SVF-2 device and therapy to treat OA of the knee.

The CPT codes are expected to become effective.





Industry experts believe that there are not enough orthopedic surgeons to handle the growth and pace of TKRs.

GID estimates its SVF-2 device and therapy will help reduce the $200BN annual U.S. healthcare costs for treating osteoarthritis of the knee.